Skip to content

Comparable Efficacy of Curcumin and Proton Pump Inhibitor for Functional Dyspepsia: A Randomized Double-blind Controlled Trial

Comparable Efficacy of Curcumin and Proton Pump Inhibitor for Functional Dyspepsia: A Randomized Double-blind Controlled Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221208003
Enrollment
210
Registered
2022-12-08
Start date
2019-06-27
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with symptoms compatible with functional dyspepsia. Functional dyspepsia Omeprazole Curcumin Turmeric

Interventions

Curcumin 250mg and Omeprazole 20mg,Curcumin 250mg and Placebo of Omeprazole 20mg,Placebo of Curcumin 250mg and Omeprazole 20mg
Curcumin and Omeprazole (C+O),Curcumin and Placebo of Omeprazole (C),Placebo of Curcumin and Omeprazole (O)

Sponsors

Ministry of Public Health, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Symptoms compatible with functional dyspepsia, 2.Age between 18 and 70 years, 3.ECOG performance status 0 or 1, 4.Not taken aspirin or NSAIDs for the past 3 months, 5.Not taken curcumin or food that significantly contained curcumin during 4 weeks before the study, 6.No symptoms of irritable bowel syndrome (constipation, diarrhea, and frequent defecation), 7.Not taken herbal medication or medication that can affect gastrointestinal symptoms and diseases, 8.Not taking PPIs during the 4 weeks before the study.

Exclusion criteria

Exclusion criteria: Patients who were pregnant/breastfeeding; had a curcumin allergy; had gallstones; had ulcers or lumps in their stomach, duodenum, or esophagus; had severe inflammation of the gastric mucosa oesophageal mucosa or intestinal mucosa; had been infected with gastric Helicobacter pylori; had diseases that would hinder the treatment of functional dyspepsia, or had symptoms or physical signs that are a warning sign of serious diseases incompatible with functional dyspepsia, were excluded from this study.

Design outcomes

Primary

MeasureTime frame
The Short-Form Leeds Dyspepsia Questionnaire Day0, Day28, and Day56 Frequency and severity of dyspepsia symptoms,Severity of Dyspepsia Assessment Day0, Day28, and Day56 Severity of Dyspepsia for randomized clinical trials

Secondary

MeasureTime frame
Adverse events Day 28 Proportion

Countries

Thailand

Contacts

Public ContactPradermchai Kongkam

Chulalongkorn University

kongkam@hotmail.com6622564246

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026